BioCentury
ARTICLE | Clinical News

Histogenics completes enrollment in Phase III of NeoCart implant

August 17, 2017 11:47 PM UTC

Histogenics Corp. (NASDAQ:HSGX) said it completed enrollment of 245 patients in a Phase III trial of its NeoCart cell therapy implant vs. standard of care (SOC) microfracture surgery to repair knee cartilage injuries.

The open-label, North American trial is evaluating the primary endpoint of change in physical functioning and pain from baseline to 1 year per both Knee injury and Osteoarthritis Outcome Score (KOOS) and International Knee Documentation Committee (IKDC) score. The secondary endpoint is cartilage repair as measured by MRI...

BCIQ Company Profiles

Histogenics Corp.